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Abstract: The objective of this exploratory, open-label, single-arm, phase II clinical trial 
was to evaluate plitidepsin (5 mg/m2) administered as a 3-hour continuous intravenous 
infusion every two weeks to patients with locally advanced/metastatic transitional cell 
carcinoma of the urothelium who relapsed/progressed after first-line chemotherapy. 
Treatment cycles were repeated for up to 12 cycles or until disease progression, 
unacceptable toxicity, patient refusal or treatment delay for >2 weeks. The primary 
efficacy endpoint was objective response rate according to RECIST. Secondary endpoints 
were the rate of SD lasting ≥6 months and time-to-event variables. Toxicity was assessed 
using NCI-CTC v. 3.0. Twenty-one patients received 57 treatment cycles. No objective 
tumor responses occurred. SD lasting <6 months was observed in two of 18 evaluable 
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patients. With a median follow-up of 4.6 months, the median PFR and the median OS were 
1.4 months and 2.3 months, respectively. The most common AEs were mild to moderate 
nausea, fatigue, myalgia and anorexia. Anemia, lymphopenia, and increases in 
transaminases, alkaline phosphatase and creatinine were the most frequent laboratory 
abnormalities. No severe neutropenia occurred. Treatment was feasible and generally well 
tolerated in this patient population; however the lack of antitumor activity precludes further 
studies of plitidepsin in this setting. 
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1. Introduction 
 
Transitional cell carcinoma (TCC) of the bladder affects 356,000 patients per year worldwide, with 
some 145,000 deaths resulting from the disease [1]. The standard first-line treatment for patients with 
advanced TCC is platinum-based combination chemotherapy like methotrexate, vinblastine, 
doxorubicin and cisplatin (MVAC), or gemcitabine  and cisplatin (GC) [2–4]. Both combinations 
achieve high response rates, although MVAC is associated with significant toxicities and a toxic death 
rate of 3–4% [2,3]. Despite this, prognosis remains poor, with an expected median survival of 
approximately one year [5,6]. Single agent and second-line treatments with ifosfamide, gemcitabine, 
paclitaxel, docetaxel or pemetrexed [7–9] after prior MVAC, produce response rates of 11–28%, but 
OS do not seem to be improved and the drug-related toxicity remains an issue in this very frail patient 
population. Thus, there is a need for second-line regimens that either improve survival outcome or 
provide a similar one with reduced toxicity. 
Plitidepsin is a cyclic depsipeptide originally isolated from the Mediterranean tunicate Aplidium 
albicans, currently produced by chemical synthesis. Plitidepsin is a COMPARE negative compound, 
whose main mechanism of action remains to be fully elucidated, although evidence suggests that 
oxidative stress [10], and decreased intracellular levels of glutathione ultimately lead to both caspases-
dependant and independent cellular apoptosis induction [11], whereas activation of the Rac1-JNK 
pathway plays a major role [12,13]. In addition, plitidepsin exhibits antiangiogenic activity through the 
inhibition of the expression of genes like the vascular endothelial growth factor (VEGF) and its 
receptor (VEGFR-1) [14–17]. Plitidepsin was found to be active, in vitro and in vivo, usually at 
concentrations as low as in the nanomolar range [18]. Human bladder 5637 cell line was found to be 
particularly sensitive to plitidepsin, with a mean IC50 of only 3.3 × 10-8 M [19]. In vivo, plitidepsin also 
showed a strong antitumor activity against subcutaneously implanted HTB-9 human bladder cell lines 
in a murine model [20,21]. 
Two schedules were selected for further phase II clinical development: a weekly regimen of  
3.2 mg/m2 on days 1, 8 and 15 every 4 weeks over 1-hour and the fortnightly regimen of 5.0 mg/m2 
over 3-hours [19,20,22–25]. Evidence for objective remission and tumor control was found in patients 
with several advanced solid tumors and hematological malignancies [26]. The dose-limiting toxicities 
(DLTs) included myalgia, muscular weakness, transient and reversible transaminase increase and 
fatigue. Remarkably, plitidepsin lacks of clinically significant bone marrow toxicity.  
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The objective of this exploratory multicenter, open-label, single-arm, phase II clinical trial was to 
assess the antitumor activity and safety profile of plitidepsin 5 mg/m2 given every two weeks as a  
3-hour intravenous (i.v.) infusion to patients with advanced TCC of the urothelium who relapsed or 
progressed after first-line chemotherapy. 
 
2. Patients and Methods 
 
Twenty-one patients participated in this study between October 2004 and December 2006 at five 
European medical centers. The protocol was approved by the institutional review board of each 
participating center, and a signed written informed consent was obtained from each patient before 
registration. 
 
2.1. Patient population 
 
The patients had unresectable, locally advanced or metastatic, and histologically-confirmed TCC of 
the bladder, ureter or renal pelvis, with documented progressive disease (PD) prior to registration and 
measurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) [27]. All 
patients had to receive no more than one previous line of systemic chemotherapy for advanced disease. 
Prior radiotherapy was allowed, but a minimum of four weeks had to elapse between the end of the 
prior radiotherapy and patient enrolment. Patients were ≥18 years old, had an Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) score of ≤2 and had recovered from any toxicity 
derived from previous treatments. Patients had an adequate organ function as defined by neutrophil 
count ≥ 1.5 × 109 /L, platelet count ≥ 100 × 109 /L, hemoglobin ≥ 9 g/dL, creatinine clearance ≥ 40 mL/min, 
serum bilirubin ≤ 1.5 mg/dL, alkaline phosphatase (AP) ≤ 2.5 × the institutional upper limit of normal 
(ULN) and up to ≤ 5 × ULN in case of extensive bone metastases, aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) ≤ 2.5 × ULN and up to ≤ 5 × ULN in case of liver metastases, 
albumin ≥ 25 g/L and normal left ventricular ejection fraction (LVEF). 
Patients were excluded if they were pregnant or lactating women or were not using adequate 
contraception methods, had a history of other neoplastic diseases (with the exception of adequately 
treated non-melanoma skin carcinoma or carcinoma in situ), had known brain or leptomeningeal 
involvement, suffered from any other relevant medical condition that may harm study participation, or 
had known hypersensitivity to plitidepsin or to any component of the reconstitution solution 
(cremophor EL, mannitol and ethanol). 
 
2.2. Study treatment 
 
Plitidepsin (Pharma Mar, Colmenar Viejo, Madrid, Spain) was infused at a dose of 5 mg/m2 as a  
3-hour i.v. infusion every 2 weeks (i.e., one cycle = two weeks). Treatment cycles were repeated for a 
maximum of 12 (~six months) or until disease progression, unacceptable toxicity, patient refusal or 
treatment delay for >2 weeks. In the event of specific toxicities after the first cycle, the dose of 
plitidepsin was to be reduced in subsequent cycles, first to 4.25 mg/m2 and then to 3.6 mg/m2. No 
further dose reductions were allowed. 
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Treatment with hematopoietic growth colony stimulating factors was allowed (except during the 
first cycle) in accordance with the guidelines of the American Society of Clinical Oncology  
(ASCO) [28]. Prophylactic treatment for emesis, which included glucocorticoids (dexamethasone  
4–8 mg i.v.), H1-receptor and serotonin (5-HT3) receptor antagonists [29], was administered  
20–30 min before each plitidepsin infusion. Patients developing grade ≥ 2 muscular toxicity could be 
empirically treated with L-carnitine (1.5 g every 8 hours) until returning to grade ≤ 1 severity. 
 
2.3. Evaluations during the study 
 
Radiological evaluation (chest X-ray, computer tomography [CT] scan or magnetic resonance 
imaging [MRI]) was required within four weeks before start of study treatment, and within six months 
prior to registration in order to document pre-baseline disease progression. While on treatment, a 
complete clinical examination was done at the end of each cycle (i.e., every two weeks). Blood 
samples for hematological and biochemistry analyses were obtained weekly during the first eight 
weeks of therapy and afterwards at least every two weeks. Creatinine clearance calculation and urine 
analysis were assessed before every cycle administration, while coagulation tests were performed 
every other cycle. LVEF measurements were repeated at 3–6 months after the start of treatment. All 
disease parameters were reassessed every eight weeks by using appropriate imaging procedures for the 
assessment of measurable and non-measurable lesions as per RECIST.  
 
2.4. Study endpoints 
 
The primary efficacy endpoint was objective tumor response rate according to RECIST in all 
patients who received a minimum of two treatment cycles. Whenever the criteria of response were met, 
re-assessment had to be repeated at least four weeks later in order to confirm response. Any eligible 
patients who died or stopped treatment because of unmanageable toxicity prior to response evaluation 
were considered non-evaluable for response. 
Secondary efficacy endpoints were the rate of stable disease (SD) lasting for at least six months and 
time-to-event variables (tumor response duration, time to progression [TTP], progression-free survival 
[PFS] and OS), and evaluation of the safety profile of plitidepsin. Patients were evaluable for toxicity 
if they had received at least one plitidepsin infusion. Treatment-related toxicities were graded 
according to National Institute of Health Common Toxicity Criteria (NCI-CTC), version 3.0 [30]. If 
toxicity persisted after the end of treatment, further assessments were performed 30 days after the 
administration of the last protocol treatment or at the resolution of all abnormalities that occurred 
during treatment. 
 
2.5. Statistical analyses 
 
A Simon’s two-stage MiniMax design was used to test the null hypothesis that the probability of 
objective response (confirmed PR or CR) was H0 ≤ 5% versus the alternative hypothesis that it was 
HA ≥ 20% [31]. After testing the drug on 18 patients in a first stage, the trial was to be terminated if no 
responses were observed. Otherwise, the trial was to go onto a second stage and other 14 patients were 
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to be evaluated to reach a total of 32 patients evaluable for efficacy. If the total number of patients 
with an objective tumor response was ≤3, this schedule was not to be considered for further evaluation. 
Descriptive statistics were used to characterize demographics, response and toxicity rates and 
laboratory observations. Time-to-event efficacy endpoints and their fixed time point rates were 
analyzed according to the Kaplan-Meier method [32]. 
 
3. Results 
 
3.1. Patient characteristics 
 
Patient and disease characteristics at baseline are shown in Table 1. The median age was 64 years, 
76.2% were males and 95.2% had an ECOG PS score of 0 or 1.  
 
Table 1. Patient and disease characteristics. 
 No. of patients (n)* % 
Gender Male 16 76.2 
 Female 5 23.8 
Age (years) Median (range) 64 (41–72) 
Performance status (ECOG) 0 4 19.0 
 1 16 76.2 
 2 1 4.8 
Tumor extension at baseline Metastatic 14 66.7 
 Locally advanced/metastatic 5 23.8 
 Locally advanced 2 9.5 
Bajorin criteria Good risk  8 38.1 
 Intermediate risk  13 61.9 
Number of sites involved Median (range) 1 (1–3) 
Sites of disease at baseline Lymph node 11 52.4 
 Liver 6 28.6 
 Lung 3 14.3 
 Soft tissue 2 9.5 
 Other** 9 42.9 
ECOG, Eastern Cooperative Oncology Group. Bajorin criteria includes: presence of visceral metastases and/or ECOG ≥ 2. 
* Data shown are n of patients except for median and range values. **One metastatic lesion in bladder, bone, mediastinum, 
pancreas, pelvis, peritoneum, kidney, suprarenal gland, and urethra was found. 
 
All patients had metastatic and/or locally advanced TCC, except for one who had poorly 
differentiated urothelial carcinoma. Patients had a median of one metastatic site (range, 1–3), with 
lymph nodes as the most common tumor site involved at baseline (52.4% of patients), followed by the 
liver (28.6%) and the lung (14.3%).  
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All patients had previously received chemotherapy (Table 2); additionally, three patients also 
received biological therapy (BCG vaccine two patients and trastuzumab one patient). Most patients 
(76.2%) had previously received cisplatin (81.0%) and gemcitabine (71.4%). All patients had 
undergone surgery, mostly consisting of radical cystectomy (71.4%), while radiotherapy had been 
administrated to 5 patients (23.8%) in the palliative setting. 
 
Table 2. Prior anticancer therapy. 
 No. of patients (n)* % 
Systemic therapy Chemotherapy 21 100.0 
 Chemotherapy/biological therapy 3 14.3 
Chemotherapy setting Advanced 16 76.2 
 Adjuvant 4 19.0 
 Neoadjuvant 1 4.8 
No. of agents of chemotherapy Median (range) 2 (1–4) 
Agents administered to ≥10% of patients Cisplatin  17 81.0 
 Gemcitabine  15 71.4 
 Methotrexate  4 19.0 
 Doxorubicin  3 14.3 
 Carboplatin  3 14.3 
Surgery . 21 100.0 
Radiotherapy Palliative 5 23.8 
* Data shown are n of patients except for median and range values. 
 
3.2. Extent of exposure 
 
A total of 57 cycles (median: two per patient; range: 1–8) were administered during the study. The 
median total cumulative dose delivered was 10.0 mg/m2 (range, 5.0–40.0 mg/m2) and the median dose 
intensity was 2.5 mg/m²/wk (range, 1.3–2.5 mg/ m2/wk), which corresponded to a median relative dose 
intensity of 99.4% (range, 52.1–101.0%). 
Cycle delays occurred in four patients (19.0%); all due to reasons unrelated to plitidepsin. The 
length of delay was 3–7 days. Thirteen patients (61.9%) discontinued treatment early because of 
disease progression, while other patients discontinued due to death as a result of disease progression  
(n = 3, 14.3%), treatment refusal (n = 2, 9.5%) and other reasons (n = 2, 9.5%) such as general 
condition deterioration and worsening of Parkinson’s disease. Only one patient (4.8%) discontinued 
due to plitidepsin-related increase in creatine phosphokinase (CPK) levels after three cycles. 
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3.3. Assessment of efficacy 
 
Three of 21 treated patients were non-evaluable for efficacy due to not having undergone any tumor 
assessments before discontinuing the study as a result of patient refusal (n = 2) and worsening of 
Parkinson’s disease (n = 1). No objective tumor responses were found among the 18 evaluable 
patients. Two patients (11.1%) achieved SD according to RECIST that lasted less than six months  
(2.2 months and 3.7 months).  With a median follow-up of 4.6 months, the median PFS was  
1.4 months (95% CI, 0.9–1.6 months) and the median OS was 2.3 months (95% CI, 1.4–4.6 months). 
 
3.4. Toxicity 
 
Table 3. Adverse events regardless of relationship with plitidepsin observed in ≥5% of patients. 
NCI-CTC  
Patients (n = 21) 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
n % n % n % n % n % 
Abdominal pain 3 14.3 2 9.5 1 4.8 . . 6 28.6 
Alopecia  2 9.5 2 9.5 NA NA NA NA 4 19.0 
Anemia 1 4.8 . . 1 4.8 . . 2 9.5 
Anorexia  5 23.8 9 42.9 1 4.8 . . 15 71.4 
Arthralgia  4 19.0 3 14.3 . . . . 7 33.3 
Constipation 4 19.0 4 19.0 1 4.8 . . 9 42.9 
Diarrhea 2 9.5 2 9.5 1 4.8 . . 5 23.8 
Dyspepsia  2 9.5 2 9.5 . . . . 4 19.0 
Dyspnea 1 4.8 2 9.5 . . 1 4.8 4 19.0 
Edema 1 4.8 3 14.3 . . . . 4 19.0 
Fatigue  3 14.3 6 28.6 8 38.1 1 4.8 18 85.7 
Fever 5 23.8 1 4.8 . . . . 6 28.6 
General physical health deterioration  . . 1 4.8 4 19.0 1 4.8 6 28.6 
Hematuria  8 38.1 . . . . . . 8 38.1 
Muscle weakness 1 4.8 2 9.5 1 4.8 . . 4 19.0 
Myalgia  4 19.0 1 4.8 1 4.8 . . 6 28.6 
Nausea 4 19.0 7 33.3 . . . . 11 52.4 
Pain 4 19.0 6 28.6 1 4.8 . . 11 52.4 
Paresthesia  6 28.6 4 19.0 . . . . 10 47.6 
Proteinuria  3 14.3 1 4.8 . . . . 4 19.0 
Urinary tract infection 3 14.3 1 4.8 1 4.8 . . 5 23.8 
Vomiting 3 14.3 4 19.0 1 4.8 . . 8 38.1 
Weight decreased  4 19.0 3 14.3 . . . . 7 33.3 
NCI-CTC, National Cancer Institute Common Toxicity Criteria.; NA, Not applicable. 
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All 21 treated patients were assessable for toxicity. Nausea (38.1% of patients), fatigue (28.6%), 
myalgia (28.6%) and anorexia (23.8%) were the most frequent adverse events (AEs) related to 
plitidepsin. No plitidepsin-related grade four AEs were observed. No plitidepsin-related 
hospitalizations or deaths occurred during the study. Table 3 shows all the AEs reported during this 
study regardless of relationship observed in at least 5% of patients. One patient received only one 
administration of L-carnitine due to muscular weakness and increased CPK levels.  
 
Table 4. Biochemical and hematological abnormalities (per patient). 
NCI-CTC  
Patients (n = 21) 
Grade 1 Grade 2 Grade 3 Grade 4 Total* 
n % n % n % n % n % 
Biochemical           
ALT increase 9 42.9 3 14.3 1 4.8 . . 13 61.9 
AP increase 8 38.1 4 19.0 4 19.0 . . 16 76.2 
AST increase 7 33.3 4 19.0 . . . . 11 52.4 
Bilirubin increase  3 14.3 1 4.8 1 4.8 . . 5 23.8 
CPK increase 5 23.8 1 4.8 . . . . 6 28.6 
Creatinine increase 10 47.6 3 14.3 . . . . 13 61.9 
Hematological**           
Anemia  10 47.6 10 47.6 1 4.8 . . 21 100.0 
Lymphopenia 4 20.0 5 25.0 1  5.0 1 5.0 11 55.0 
Neutropenia 1 5.0 . . . . . . 1 5.0 
Thrombocytopenia  4 19.0 . . . . . . 4 19.0 
* Total number of patients and cycles with data available for each parameter. ** No patients had leukopenia of any grade 
during the study. ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CPK, 
creatine phosphokinase; NCI-CTC, National Cancer Institute Common Toxicity Criteria. 
 
The most frequent biochemical abnormalities were transient and asymptomatic increase in AP 
(76.2% of patients), creatinine (61.9%) and hepatic transaminases (ALT: 61.9% and AST: 52.4%) 
(Table 4). Grade 3 AP increases occurred in 4 patients, whereas one patient had grade 3 ALT increase. 
Additionally, one patient had grade 3 bilirubin increase after one cycle. No patients had grade 3/4 
increases in AST, creatinine or CPK levels. 
The most common hematological abnormalities were anemia and lymphopenia, which were 
observed in 21 (100.0%) and 11 (55.0%) patients, respectively (Table 4). Anemia and lymphopenia 
were grade 3 in one patient each; however grade 3 lymphopenia was already present at baseline. 
Additionally, one patient had grade 4 lymphopenia after cycle 3. No patients showed leukopenia of 
any grade, whereas the cases of neutropenia and thrombocytopenia found during the study were  
grade 1 only. 
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4. Discussion 
 
This exploratory, phase II study of plitidepsin 5 mg/m2 given every two weeks as a 3-hour infusion 
showed poor antitumor activity among 18 evaluable pretreated patients with locally advanced or 
metastatic TCC of the urothelium who relapsed or progressed after first-line chemotherapy. No 
objective tumor responses were found and only two patients achieved SD according to RECIST, but 
these were short-lasting (less than six months). 
The optimal agents and regimens for second-line chemotherapy in advanced TCC still remain 
undefined. Both single-agent and combination regimens have been evaluated as potential therapies 
[33]. Recently, Di Lorenzo et al. have reported that the combination of paclitaxel and 
cyclophosphamide was well tolerated and associated with promising 31% response rate in previously 
treated patients [34]. With respect to single-agent chemotherapy, gemcitabine alone has shown a 
higher response rate (23–25%) in prior unexposed patients than docetaxel, paclitaxel and ifosfamide 
(10–20%) [7,35–38], although its incorporation as part of standard fist line regimens makes unclear its 
utility in the relapse setting. Unfortunately, among several newer compounds evaluated in this setting 
bortezomib [39], sunitinib [40], ixabepilone [41] and aflibercept [42] all have shown very limited or no 
efficacy. Only vinflunine, a novel vinka alkaloid class compound, has shown comparable activity to 
taxanes or ifosfamide in a large phase II study with a 14.6% response rate evaluated by the 
independent review committee (IRC) [43]. Thus, clearly newer active agents are needed. 
In the current study, as a result of lack of objective responses with this biweekly plitidepsin 
regimen, patient recruitment did not progress into the second stage and the trial was early closed. 
Patient population was comparable to other studies regarding number of previous lines, disease 
extension and ECOG PS. Clinical benefit with single-agent plitidepsin has been found in patients with 
other advanced solid tumor types, particularly in chemo-refractory tumors as renal, melanoma, 
hepatocellular carcinoma and carcinoid tumors and in  hematological malignancies (e.g., multiple 
myeloma and non-cutaneous peripheral T-cell lymphoma) [24]. 
Toxicity with plitidepsin in patients with locally advanced or metastatic TCC mostly consisted of 
mild or moderate AEs (nausea, fatigue, myalgia and anorexia) and was in accordance with the 
toxicities observed when plitidepsin was administered to patients with other malignancies [23,25]. The 
most common laboratory abnormalities were anemia and lymphopenia, and reversible and 
asymptomatic increases in transaminases, AP and creatinine. Neither clinically significant neutropenia 
nor thrombocytopenia occurred in this frail patient population. 
 
5. Conclusions 
 
In conclusion, the lack of significant antitumor activity despite a favorable safety profile suggests 
that further studies of plitidepsin as a single agent in TCC of the urothelium are not warranted; 
however its lack of overlapping toxicity with other chemotherapeutic agents, as well as the presence of 
additivity or synergy in preclinical models with compounds like carboplatin, gemcitabine and/or 
taxanes, open some new options for this drug in the future. 
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